Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

Stopped The study was terminated early due to lack of efficacy after 10 participants enrolled.

Conditions

• Tuberculosis

Interventions

• DRUG: Delamanid
• DRUG: Optimized Background Regimen (OBR)

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.